Risk prediction models for colorectal cancer: A systematic review

Cancer Prevention Research

Volumn 9, Issue 1, 2016, Pages 13-26

  Usher Smith, Juliet A ^a   Walter, Fiona M ^a,b   Emery, Jon D ^a,b   Win, Aung K ^c   Griffin, Simon J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; BODY MASS; CALIBRATION; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; COLORECTAL CANCER; FAMILY HISTORY; FEASIBILITY STUDY; HUMAN; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK PREDICTION MODEL; SYSTEMATIC REVIEW; VALIDATION STUDY; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; INCIDENCE; MASS SCREENING; METABOLISM; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

TUMOR MARKER;

AREA UNDER CURVE; BIOMARKERS, TUMOR; BODY MASS INDEX; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MASS SCREENING; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84955300407     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0274     Document Type: Review

References (84)

1. Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014;136:E359-86.
2. Cancer Research UK (2009). By stage at diagnosis. London: Cancer Research UK.
3. Hardcastle JD, Chamberlain JO, RobinsonMH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
4. Holme O, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane database Syst Rev 2013; 9:CD009259.
5. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
6. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008;95:1029-36.
7. Hall WD, Mathews R, Morley KI. Being more realistic about the public health impact of genomic medicine. PLoS Med 2010;7: e1000347.
8. Win AK, Macinnis RJ, Hopper JL, Jenkins MA. Risk prediction models for colorectal cancer: a review. Cancer Epidemiol Biomarkers Prev 2012;21: 398-410.
9. Ma GK, Ladabaum U. Personalizing colorectal cancer screening: a systematic review of models to predict risk of colorectal neoplasia. Clin Gastroenterol Hepatol 2014;12:1624-34.e1.
10. Collins GS, Reitsma JB, Altman DG,Moons KGM. Transparent reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement. Ann Intern Med 2015;162: 55-63.
11. Villadiego-Sanchez JM,Ortega-Calvo M, Pino-Mejías R, Cayuela A, Iglesias-Bonilla P, García-de La Corte F, et al. Multivariate explanatory model for sporadic carcinoma of the colon in Dukes' stages I and IIa. Int J Med Sci 2009;6:43-50.
12. García-Bilbao A, Armañanzas R, Ispizua Z, Calvo B, Alonso-Varona A, Inza I, et al. Identification of a biomarker panel for colorectal cancer diagnosis. BMC Cancer 2012;12:43.
13. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, KibiM, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 2012;7:1-10.
14. Pengjun Z, Xinyu W, Feng G, Xinxin D, Yulan L, Juan L, et al. Multiplexed cytokine profiling of serum for detection of colorectal cancer. Future Oncol 2013;9:1017-27.
15. Emmons K, Koch-Weser S, Atwood K, Conboy L, Rudd R, Colditz G. A qualitative evaluation of the harvard cancer risk index. J Health Commun 1999;4:181-93.
16. Emmons KM, Wong M, Puleo E, Weinstein N, Fletcher R, Colditz G. Tailored computer-based cancer risk communication: correcting colorectal cancer risk perception. J Health Commun 9:127-41.
17. Kim DJ, Rockhill B, Colditz GA. Validation of the Harvard Cancer Risk Index: a prediction tool for individual cancer risk. J Clin Epidemiol 2004;57:332-40.
18. Park Y, Freedman AN, Gail MH, Pee D, Hollenbeck A, Schatzkin A, et al. Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. J Clin Oncol 2009;27:694-8.
19. Schroy PC, Coe AM, Mylvaganam SR, Ahn LB, Lydotes MA, Robinson PA, et al. The your disease risk index for colorectal cancer is an inaccurate risk stratification tool for advanced colorectal neoplasia at screening colonoscopy. Cancer Prev Res 2012;5:1044-52.
20. Yip K-T, Das PK, Suria D, Lim C-R, Ng G-H, Liew C-C. A casecontrolled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res 2010;29:128.
21. Betes M, Muñoz-Navas MA, Duque JM, Angos R, Macías E, Subtil JC, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol 2003;98:2648-54.
22. Cai QC, Da Yu E, Xiao Y, Bai WY, Chen X, He LP, et al. Derivation and validation of a prediction rule for estimating advanced colorectal neoplasm risk in average-risk chinese. Am J Epidemiol 2012;175: 584-93.
23. Chen G, Mao B, Liu Q, Qian J, Liu L. Derivation and validation of a prediction rule for estimating colorectal neoplasm risk in asymptomatic individuals in southern Jiangsu province. World J Gastroenterol 2013;21: 4043-9.
24. Chen G, Mao B, Pan Q, Liu Q, Xu X, Ning Y. Prediction rule for estimating advanced colorectal neoplasm risk in average-risk populations in southern Jiangsu Province. Chin J Cancer Res 2014;26:4-11.
25. Hassan C, Pooler BD, Kim DH, Rinaldi A, Repici A, Pickhardt PJ. Computed tomographic colonography for colorectal cancer screening: risk factors for the detection of advanced neoplasia. Cancer 2013;119:2549-54.
26. Kaminski MF, Polkowski M, Kraszewska E, Rupinski M, Butruk E, Regula J. A score to estimate the likelihood of detecting advanced colorectal neoplasia at colonoscopy. Gut 2014;63:1112-9.
27. Lin OS, Kozarek RA, Schembre DB, Ayub K,Gluck M, Cantone N, et al. Risk stratification for colon neoplasia: screening strategies using colonoscopy and computerized tomographic colonography. Gastroenterology 2006; 131:1011-9.
28. Lin Y, Yu M, Wang S, Chappell R, Imperiale TF. Advanced colorectal neoplasia risk stratification by penalized logistic regression. Stat Methods Med Res 2013;0:0-15.
29. Stegeman I, de Wijkerslooth TR, Stoop EM, van Leerdam ME, Dekker E, van Ballegooijen M, et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 2014;63: 466-71.
30. Stegeman I, de Wijkerslooth TR, Stoop EM, van Leerdam ME, Dekker E, van Ballegooijen M, et al. Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer. Cancer Epidemiol 2013;37: 278-83.
31. Tao S,Hoffmeister M, BrennerH. Development and validation of a scoring system to identify individuals at high risk for advanced colorectal neoplasms who should undergo colonoscopy screening. Clin Gastroenterol Hepatol 2014;12:478-85.
32. Yeoh K-G, Ho K-Y, Chiu H-M, Zhu F, Ching JYL, Wu D-C, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut 2011;60:1236-41.
33. Almurshed KS. Colorectal cancer: case-control study of sociodemographic, lifestyle and anthropometric parameters in Riyadh. East Mediterr Heal J 2009;15:817-26.
34. Camp NJ, Slattery ML. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control 2002;13:813-23.
35. Colditz GA, Atwood KA, Emmons K, Monson RR, Willett WC, TrichopoulosD, et al. Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 2000;11:477-88.
36. Driver JA, Gaziano JM, Gelber RP, Lee I-M, Buring JE, Kurth T. Development of a risk score for colorectal cancer in men. Am J Med 2007;120:257-63.
37. Freedman AN, Slattery ML, Ballard-Barbash R, Willis G, Cann BJ, Pee D, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 2009;27:686.
38. Ma E, Sasazuki S, Iwasaki M, Sawada N, Inoue M. 10-Year risk of colorectal cancer: development and validation of a prediction model in middle-aged Japanese men. Cancer Epidemiol 2010;34:534-41.
39. Shin A, Joo J, YangH-R, Bak J, Park Y, Kim J, et al. Risk prediction model for colorectal cancer: national health insurance corporation study, Korea. PLoS One 2014;9:e88079.
40. Wei EK, Colditz GA, Giovannucci EL, Fuchs CS, Rosner BA. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the nurses' health study. Am J Epidemiol 2009;170:863-72.
41. Wei EK, Giovannucci E, Wu K, Rosner B, Charles S, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer 2004;108:433-42.
42. Bener A, Moore MA, Ali R, El Ayoubi HR. Impacts of family history and lifestyle habits on colorectal cancer risk: a case-control study inQatar. Asian Pacific J Cancer Prev 2010;11:963-8.
43. Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, Koessler T, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals. Gut 2012;62:871-81.
44. Guesmi F, Zoghlami A, Sghaiier D, Nouira R, Dziri C. Alimentary factors promoting colorectal cancer risk: a prospective epidemiological study. Tunis Med 2010;88:184-9.
45. Han M, Choong TL, Hong WZ, Chao S, Zheng R, Kok TY, et al. Novel bloodbased, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 2008;14:455-60.
46. Jo J, Nam CM, Sull JW, Yun JE, Kim SY, Lee SJ, et al. Prediction of colorectal cancer risk using a genetic risk score: The KoreanCancer Prevention Study-II (KCPS-II). Genomics Inform 2012;10:175.
47. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Metaanalyses of colorectal cancer risk factors. Cancer Causes Control 2013; 24:1207-22.
48. Lubbe SJ, Di Bernardo MC, Broderick P, Chandler I, Houlston RS. Comprehensive evaluation of the impact of 14 genetic variants on colorectal cancer phenotype and risk. Am J Epidemiol 2012;175:1-10.
49. Marshall KW, Mohr S, El Khettabi F, Nossova N, Chao S, Bao W, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer 2010;126:1177-86.
50. Taylor DP, Stoddard GJ, Burt RW, Williams MS, Mitchell JA, Haug PJ, et al. How well does family history predict who will get colorectal cancer? Implications for cancer screening and counseling. Genet Med 2011;13: 385-91.
51. Wang HM, Chang TH, Lin FM, Chao TH, Huang WC, Liang C, et al. A new method for post Genome-Wide Association Study (GWAS) analysis of colorectal cancer in Taiwan. Gene 2013;518:107-13.
52. Wei Y-S, Lu J-C, Wang L, Lan P, Zhao H-J, Pan Z-Z, et al. Risk factors for sporadic colorectal cancer in southern Chinese. World J Gastroenterol 2009;15:2526-30.
53. Wells BJ, Kattan MW, Cooper GS, Jackson L, Koroukian S. ColoRectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study. J Am Board Fam Med 2014;27:42-55.
54. Yarnall JM, Crouch DJM, Lewis CM. Incorporating non-genetic risk factors and behavioural modifications into risk prediction models for colorectal cancer. Cancer Epidemiol 2013;37:324-9.
55. Amir E, FreedmanOC, Seruga B, Evans DG. Assessingwomen at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010;102:680-91.
56. Usher-Smith JA, Emery J, Kassianos AP, Walter FM. Risk prediction models for melanoma: a systematic review. Cancer Epidemiol Biomarkers Prev 2014;23:1450-63.
57. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
58. Marchand LL. Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. J Natl Cancer Inst Monogr 1999;26:101-5.
59. Hewitson P, Glasziou P,Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
60. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012;61:1036-40.
61. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
62. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375:1624-33.
63. Segnan N, Armaroli P, Bonelli L, RisioM, Sciallero S, Zappa M, et al. Onceonly sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst 2011;103:1310-22.
64. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology 2014;146:709-17.
65. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467.
66. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Longterm colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-105.
67. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011;33:88-100.
68. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104.
69. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am 2002;12:93-109.
70. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, et al. Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009;70:96-108, 108.e1-24.
71. Seeff LC, Manninen DL, Dong FB, Chattopadhyay SK, Nadel MR, Tangka FKL, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology 2004;127:1661-9.
72. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Aliment Pharmacol Ther 2004;20:507-15.
73. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal antiinflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007;146:361-4.
74. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic reviewprepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:365-75.
75. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
76. Joseph DA, King JB, Miller JW, Richardson LC. Prevalence of colorectal cancer screening among adults-Behavioral Risk Factor Surveillance System, United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61 Suppl:51-6.
77. Felsen CB, Piasecki A, Ferrante JM, Ohman-Strickland PA, Crabtree BF. Colorectal cancer screening among primary care patients: does risk affect screening behavior? J Community Health 2011;36:605-11.
78. Blalock SJ, DeVellis BM, Afifi RA, Sandler RS. Risk perceptions and participation in colorectal cancer screening. Health Psychol 1990;9:792-806.
79. Beydoun HA, Beydoun MA. Predictors of colorectal cancer screening behaviors among average-risk older adults in the United States. Cancer Causes Control 2008;19:339-59.
80. Straus WL, Mansley EC, Gold KF, Wang Q, Reddy P, Pashos CL. Colorectal cancer screening attitudes and practices in the general population: a riskadjusted survey. J Public Health Manag Pract 2005;11:244-51.
81. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000;11:579-88.
82. Parkin DM, Olsen A-H, Sasieni P. The potential for prevention of colorectal cancer in the UK. Eur J Cancer Prev 2009;18:179-90.
83. Emmons KM, McBride CM, Puleo E, Pollak KI, Clipp E, Kuntz K, et al. Project PREVENT: a randomized trial to reduce multiple behavioral risk factors for colon cancer. Cancer Epidemiol Biomarkers Prev 2005;14: 1453-9.
84. Houlston RS. COGENT (COlorectal cancer GENeTics) revisited. Mutagenesis 2012;27:143-51.